Correlation Between Champions Oncology and CytomX Therapeutics

Can any of the company-specific risk be diversified away by investing in both Champions Oncology and CytomX Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Champions Oncology and CytomX Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Champions Oncology and CytomX Therapeutics, you can compare the effects of market volatilities on Champions Oncology and CytomX Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Champions Oncology with a short position of CytomX Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Champions Oncology and CytomX Therapeutics.

Diversification Opportunities for Champions Oncology and CytomX Therapeutics

0.26

Correlation Coefficient

Champions Oncology  CytomX Therapeutics

Modest diversification

The 3 months correlation between Champions and CytomX is 0.26. Overlapping area represents the amount of risk that can be diversified away by holding Champions Oncology and CytomX Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CytomX Therapeutics and Champions Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Champions Oncology are associated (or correlated) with CytomX Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CytomX Therapeutics has no effect on the direction of Champions Oncology i.e., Champions Oncology and CytomX Therapeutics go up and down completely randomly.

Pair Corralation between Champions Oncology and CytomX Therapeutics

Given the investment horizon of 90 days Champions Oncology is expected to generate 1.06 times less return on investment than CytomX Therapeutics. In addition to that, Champions Oncology is 1.22 times more volatile than CytomX Therapeutics. It trades about 0.03 of its total potential returns per unit of risk. CytomX Therapeutics is currently generating about 0.04 per unit of volatility. If you would invest  118.00  in CytomX Therapeutics on September 5, 2024 and sell it today you would earn a total of  5.00  from holding CytomX Therapeutics or generate 4.24% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Champions Oncology  vs.  CytomX Therapeutics

Champions Oncology

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Champions Oncology are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating fundamental drivers, Champions Oncology may actually be approaching a critical reversion point that can send shares even higher in January 2025.

CytomX Therapeutics

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in CytomX Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating primary indicators, CytomX Therapeutics may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Champions Oncology and CytomX Therapeutics

The main advantage of trading using opposite Champions Oncology and CytomX Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Champions Oncology position performs unexpectedly, CytomX Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CytomX Therapeutics will offset losses from the drop in CytomX Therapeutics' long position.

The idea behind Champions Oncology and CytomX Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.